BP-897
 | |
| Clinical data | |
|---|---|
| ATC code |
|
| Identifiers | |
| |
JSmol) | |
| |
| |
  (what is this?) (verify) | |
BP-897 is a drug used in scientific research which acts as a potent selective
D3 receptor partial agonist with an in vitro intrinsic activity of ~0.6 and ~70x greater affinity for D3 over D2 receptors and is suspected to have partial agonist or antagonist activity in vivo.[1] It has mainly been used in the study of treatments for cocaine addiction.[2][3][4][5][6][7][8] A study comparing BP-897 with the potent, antagonistic, and highly D3 selective SB-277,011-A found, "SB 277011-A (1–10 mg/kg) was able to block cue-induced reinstatement of nicotine-seeking, indicating that DRD3 selective antagonism may be an effective approach to prevent relapse for nicotine. In contrast, BP 897 did not block the cue-induced reinstatement of nicotine-seeking or nicotine-taking under the FR5 schedule."[9]